Titre | A Phase II Study of Durvalumab Treatment Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity Substudy B: For Continued Treatment (=/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies |
Protocole ID | IND.238 |
ClinicalTrials.gov ID | NCT03847649 |
Type(s) de cancer | Tumeurs solides |
Phase | Phase II |
Type étude | Clinique |
Médicament | Durvalumab |
Institution |
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS 1401 18e Rue, Québec, QC, G1J 1Z4 |
Ville | Québec |
Investigateur(trice) principal(e) |
Dr André Blais |
Coordonnateur(trice) | |
Statut | Actif en recrutement |
Date d'activation | 22-09-2022 |
Critètes d'éligibilité |
Les plus pertinents
|
Critètes d'exclusion |
Les plus pertinents
|